Cell Banking Outsourcing Market 2024 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2030

The global market value of the cell banking outsourcing market was valued at USD 10.7 billion in 2022, and a CAGR of 18.1% is expected during the forecast period. Increasing adoption of stem cell therapy and growing demand for monoclonal antibodies are driving the market's growth significantly. Increasing demand for cell and gene-based therapy is propelling market growth. It’s a rapidly growing sector within biotechnology and pharmaceuticals, driven by the need for specialized expertise and cost-effective solutions in managing valuable cell lines used for research, development, and the production of therapeutics. This outsourcing allows companies to focus on their core activities while leveraging external expertise for cell line management. Increasing research and development worldwide and technological advancements are driving the growth of the cell banking outsourcing market.

Impact of Covid-19

COVID-19 significantly impacted the cell banking outsourcing market. Initially, disruptions in the supply chain, limited lab access, and workforce restrictions affected operations. However, the pandemic also accelerated demand for cell-based therapies and vaccines, driving increased outsourcing for cell banking services. There is an increase in demand for robust and flexible outsourcing strategies to ensure continuity in research, development, and manufacturing processes despite global disruptions. With an increasing culture of remote work adoption and stringent safety protocols, the market had to face challenges. Overall, COVID-19 had a negative impact on the cell banking outsourcing market.

Growth Drivers

Increasing demand for biopharmaceuticals: the rising need for biopharmaceuticals and cell-based therapies fuels the demand for efficient cell banking services to support their development and production. Advancements in cell culture techniques, cryopreservation, and cell line authentication drive the need for outsourcing partners with cutting-edge technologies and methodologies.

Cost-effectiveness and efficiency: Outsourcing cell banking services should be cost-effective compared to in-house infrastructure set-up and maintenance, allowing companies to allocate resources strategically. Stringent regulatory requirements push companies to seek expertise in compliance standards and quality assurance offered by specialized outsourcing providers.

Pandemic Induced Demand: The covid-19 pandemic heightened the need for reliable outsourcing partners to ensure continuity in research, development, and production despite disruptions.

Segmentation

Bank Types

·         Master Cell Banks

·         Working Cell Banks

·         Viral Cell Banks

By Phase

·         Bank Storage

·         Cell Storage Stability Testing

·         Bank Preparation

·         Bank Characterization and Testing

·         Others

By Cell-Type

Stem Cell

·         Cord Blood Stem Cell Testing

·         Embryonic Stem Cell Banking

·         Adult Stem Cell Banking

·         Dental Stem Cell Banking

·         Induced Pluripotent Stem Cell Banking

Non-Stem Cell

Regional Outlook

·         Asia Pacific

·         North America

·         Latin America

·         Europe

·         Middle East and Africa

Cell Banking Outsourcing Market Bank Types Segmentation

On the basis of bank types, the cell banking outsourcing market is segmented into matrix cell banks, working cell banks, and viral cell banks. Master cell banks are well characterized and well known for their quality and consistency. They are derived from high-quality cells and undergo demanding testing and analysis to ensure that they meet precise standards for identity, purity, stability, and safety. These are intended to be the source for long-term production. They provide a continuous and steady supply of cells for the production of vaccines. MCBs help avoid expensive and time-consuming troubleshooting. Working cell banks and viral cell banks are critical components in biopharmaceutical manufacturing. Working cell banks consist of cells used to produce therapeutic proteins or other biologics. While virus cell banks contain cells infected with a specific virus used to produce viral-based therapies like vaccines or viral vectors for gene therapies, Both are essential for ensuring the consistent production and quality of biopharmaceutical products.

Cell Banking Outsourcing by Phase Segmentation

On the basis of phase, cell banking outsourcing is segmented into bank storage, cell storage stability testing, bank preparation, bank characterization and testing, and others. Bank storage is the leading segment and is expected to dominate significantly during the forecast period. It refers to the storage of pharmaceutical products in large quantities under controlled conditions in a warehouse or facility by manufacturers or distributors. Cell storage is another leading segment that relates to the storage of biological materials, like cells or tissues, in specialized conditions such as laboratories or cell banks. Stability testing is conducted to evaluate how the quality of a pharmaceutical product varies over time. Increasing growth in the biotechnology sector is boosting the growth of the market.

Regional Outlook

On the basis of the regions, the cell banking outsourcing market is segmented into 5 types: Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America is expected to dominate the cell banking outsourcing market during the forecast period. Increasing demand for biopharmaceuticals and increasing growth in stem cell therapy are leading the market significantly. The United States, Canada, and Mexico are the big markets due to the presence of key major players. Increasing growth in research and development is driving the growth of the market significantly.

The United States, in particular, has a regulatory environment that promotes biopharmaceuticals and research. Food and drug administrations in the United States provide clear and well-established criteria for many parts of the biopharmaceutical industry. North America is home to a plethora of biopharmaceutical companies. The Asia-Pacific region holds significant potential in the cell banking outsourcing market due to several factors. It benefits from a growing biotechnology sector and supportive regulatory environments in countries like China, India, and Japan. Lower operational costs and increasing investments in research and development are driving the growth in the market significantly.

Europe, especially western Europe, including Germany, France, Italy, and the United Kingdom, is a robust market driven by a strong biotechnology and pharmaceutical industry. The region boosts stringent regulatory standards, fostering trust and quality assurance in outsourced services. Leveraging advanced technologies and expertise makes Europe an attractive hub for cell banking outsourcing due to its established infrastructure. South Africa, Nigeria, Egypt, Brazil, Argentina, and Columbia are witnessing moderate growth during the forecast period. The presence of some key players in these regions is expected to drive growth during the forecast period.

Key Players

·         Covance

·         Goodwin Biotechnology

·         BSL Bio service

·         SGS

·         Lonza

·         Life cell International

·         Reliance Life Science

·         Cord Life Group Limited

·         Charles River Laboratories

·         Labcorp Drug Development

·         Perfectus Biomed Limited

·         Other Players